Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
XenTech logo — Premium quality preclinical oncology CRO, pioneering the PDX...

XenTech

Premium quality preclinical oncology CRO, pioneering the PDX technology for more than 16 years.

Founded 2006 France France 36 employees Seed Total: $600.00K Biotechnology, Health Care +1

General Information

Company Name XenTech
Founded Year 2006
Location France France +1
Employees 36
Industries Biotechnology, Health Care, Life Sciences
Funding Stage Seed
Social

Get notified when XenTech moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About XenTech

XenTech is a biotech/Contract Research Organization (CRO) founded in 2006 in France. The company specializes in translational research in oncology, offering preclinical services to assess the anti-cancer potential of drug candidates, including PDX and CDX. With a slogan of "Premium quality preclinical oncology CRO, pioneering the PDX technology for more than 16 years," XenTech has positioned itself as a leader in the industry. In addition to its services, XenTech also conducts internal R&D programs aimed at correlating drug response with molecular features of tumors, and identifying cancer biomarkers and therapeutic targets. The company secured a €600.00K Seed Round investment on 31 October 2008, with the investment coming from Aurinvest. With its focus on oncology and the growing demand for personalized medicine, XenTech is well-positioned to capitalize on the increasing emphasis on targeted therapies in the field of cancer treatment. The company's combination of preclinical services, internal R&D, and pioneering PDX technology make it an attractive prospect for investors looking to support advancements in oncology research.

Taxonomy: oncology, preclinical research, drug efficacy evaluation, biomarker identification, therapeutic target identification, PDX technology, patient-derived tumor xenografts, contract research organization, in vivo assays, in vitro assays, translational research, biotech, cancer research, R&D programs

Services & Products

Development of preclinical drug testing models
profiling studies
and innovative solutions for drug development in oncology

Target Customers

Biopharmaceutical companies academic institutions research hospitals and cancer research organizations

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round •••••• 1
Investor
31 Oct 2008
Non Equity Assistance •••••• 1 •••• •••• 25 Apr 2006

XenTech Alternatives & Competitors

XenTech vs
INOVOTION
INOVOTION France

Which molecule will stand out

Grant
19 employees
Biotechnology, Health Care
Compare XenTech vs INOVOTION
XenTech vs
ApoGen Biotechnologies, Inc.
ApoGen Biotechnologies, Inc. United States

As the arsenal of available cancer therapies has grown and evolved from cytotoxic chemotherapy to ta...

Series A
1 employees
Biotechnology, Health Care
Compare XenTech vs ApoGen Biotechnologies, Inc.
XenTech vs
PreComb
PreComb Switzerland

AI-guided Functional Precision Medicine

Series A
11 employees
Compare XenTech vs PreComb

FAQ About XenTech

Premium quality preclinical oncology CRO, pioneering the PDX technology for more than 16 years.
XenTech was founded in 2006.
XenTech is headquartered in France.
XenTech operates in the following industries: Biotechnology, Health Care, Life Sciences.
XenTech has approximately 36 employees.
XenTech has completed 2 funding rounds, raising a total of $600.00K. The latest funding stage is Seed.
XenTech offers: Development of preclinical drug testing models, profiling studies, and innovative solutions for drug development in oncology.
Top alternatives and competitors to XenTech include INOVOTION, ApoGen Biotechnologies, Inc., PreComb, The Center for Cancer and Metabolism, Cornerstone Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
XenTech and INOVOTION are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors XenTech and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes